Amgen said Thursday that it will acquire the small drugmaker ChemoCentryx for $4 billion to obtain a newly approved medicine that treats patients with a serious autoimmune condition.
ChemoCentryx is being purchased for $52 per share, or a 116% premium to its Wednesday closing price.
The centerpiece of Amgen’s acquisition is a pill called Tavneos that treats patients with ANCA-associated vasculitis, an autoimmune disease that causes inflammation, blockage, and damage to small blood vessels. People with the disorder are at high risk for organ damage, often in the kidneys and lungs.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
